Breast Cancer Research and Treatment

, Volume 28, Issue 2, pp 179–193 | Cite as

Breast cancer prevention through modulation of endogenous hormones

  • Darcy V. Spicer
  • Malcolm C. Pike
Article

Summary

The use of exogenous sex-steroids for hormonal contraception is important to the way of life of many modern women. The widespread use of hormonal contraceptives represents a unique opportunity to have a substantial positive impact on women's health. The observation that users of oral combination type contraceptives have a reduced risk of ovarian cancer should encourage the extension of contraceptive development to address the most important malignancy facing modern women, breast cancer. Epidemiological evidence strongly suggests that both estrogens and progestogens contribute to breast cancer risk, and account for the steep rise in risk seen during the premenopausal years. Studies of normal breast epithelial cell proliferation confirm that progestogens are breast mitogens, and explain why current contraceptives, which are progestogen dominant, do not prevent breast cancer. A long-acting depot contraceptive can be developed which releases: 1) an agonist of gonadotropin releasing hormone to suppress ovarian function; and 2) sex-steroids at doses below those in current contraceptives, and below those associated with ovulation. Such a contraceptive should provide substantial life-time protection against both breast and ovarian cancer, and would retain many of the other health benefits of current contraceptives.

Key words

contraception breast cancer prevention cell proliferation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vessey MP: An overview of the benefits and risks of combined oral contraceptives (the Jephcott Lecture, 1989).In: Mann RD (ed) Oral Contraceptives and Breast Cancer. Parthenon Publishing Group, Park Ridge, 1990, pp 121–132.Google Scholar
  2. 2.
    Centers for Disease Control: Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 256:796–800, 1987.Google Scholar
  3. 3.
    Whittemore AS, Harris R, Itnyre J, and the Collaborative Ovarian Cancer Group: Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial cancers in white women. Am J Epidemiol 136:1184–1203, 1992.Google Scholar
  4. 4.
    Pike MC, Spicer DV. Oral contraceptives and cancer.In: Shoupe D, Haseltine F (ed) Contraception. Springer-Verlag, New York, 1993, in press.Google Scholar
  5. 5.
    Henderson B, Ross R, Pike M, Casagrande J: Endogenous hormones as a major factor in human cancer. Cancer Res 42:3232–3239, 1982.Google Scholar
  6. 6.
    Pike M: Age-related factors in cancer of the breast, ovary and endometrium. J Chron Dis 40:59–69, 1987.Google Scholar
  7. 7.
    Key TJA, Pike MC: The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57:205–212, 1988.Google Scholar
  8. 8.
    Pike MC, Bernstein L, Spicer DV: Exogenous hormones and breast cancer risk.In: Niederhuber JE (ed) Current Therapy in Oncology. B.D. Decker/Mosby Year Book, St. Louis MO, 1993, pp 292–303.Google Scholar
  9. 9.
    Pike MC, Ross RK, Lobo RA, Key TJA, Potts M, Henderson BE: LHRH agonists and the prevention of breast and ovarian cancer. Br J Cancer 60:142–148, 1989.Google Scholar
  10. 10.
    Spicer DV, Shoupe D, Pike M: GnRH agonists as contraceptive agents: Predicted significantly reduced risk of breast cancer. Contraception 44:289–310, 1991.Google Scholar
  11. 11.
    Ames BN, Gold LS: Too many rodent carcinogens: Mitogenesis increases mutagenesis. Science 249:970–971, 1990.Google Scholar
  12. 12.
    Cohen SM, Ellwein L: Cell proliferation in carcinogenesis. Science 249:1007–1011, 1990.Google Scholar
  13. 13.
    Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE: Increased cell division as a cause of human cancer. Cancer Res 50:7415–7421, 1990.Google Scholar
  14. 14.
    Butterworth B, Slaga T: Chemically Induced Cell Proliferation: Implications for Risk Assessment. Wiley-Liss, New York, 1991.Google Scholar
  15. 15.
    Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. Epidemiol Rev 15:17–35, 1993.Google Scholar
  16. 16.
    Meyer JS: Cell proliferation in normal human breast ducts, fibroadenomas, and other duct hyperplasias, measured by nuclear labeling with tritiated thymidine. Hum Pathol 8:67–81, 1977.Google Scholar
  17. 17.
    Anderson TJ, Ferguson DJP, Raab GM: Cell turnover in the “resting” human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 46:376–382, 1982.Google Scholar
  18. 18.
    Longacre TA, Bartow SA: A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Path 10:382–393, 1986.Google Scholar
  19. 19.
    Anderson TJ, Battersby S, King RJB, McPherson K, Going JJ: Oral contraceptive use influences resting breast proliferation. Hum Pathol 20:1139–1144, 1989.Google Scholar
  20. 20.
    Williams G, Anderson E, Howell A: Oral contraceptive use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 48:206–210, 1991.Google Scholar
  21. 21.
    Battersby A, Anderson TJ: Proliferative and secretory activity in the pregnant and lactating human breast. Virchows Archiv A Pathol Anat 413:189–196, 1988.Google Scholar
  22. 22.
    Meyer JS, Connor RE: Cell proliferation in fibrocystic disease and postmenopausal breast ducts measured by thymidine labeling. Cancer 50:746–751, 1982.Google Scholar
  23. 23.
    Haslam SZ: Progesterone effects on deoxyribonucleic acid synthesis in normal mouse mammary glands. Endocrinol 122:464–470, 1988.Google Scholar
  24. 24.
    Wang S, Counterman LJ, Haslam SZ: Progesterone action in normal mouse mammary gland. Endocrinol 127:2183–2190, 1990.Google Scholar
  25. 25.
    Coleman S, Silberstein GB, Daniel CW: Ductal morphogenesis in the mouse mammary gland: evidence supporting a role for epidermal growth factor. Devel Biol 127:304–315, 1988.Google Scholar
  26. 26.
    Coleman S, Daniel CW: Inhibition of mouse mammary ductal morphogenesis and down-regulation of the EGF receptor by epidermal growth factor. Devel Biol 137:425–433, 1990.Google Scholar
  27. 27.
    Haslam SZ, Counterman LJ, Nummy KA: Effects of epidermal growth factor, estrogen and progestin on DNA synthesis in mammary cells in vivo are determined by the developmental state of the gland. J Cell Physiol 155:72–78, 1993.Google Scholar
  28. 28.
    Haslam SZ, Counterman LJ, Nummy KA: EGF receptor regulation in normal mouse mammary gland. J Cell Physiol 152:553–557, 1992.Google Scholar
  29. 29.
    Silberstein GB, Flanders KC, Roberts AB, Daniel CV: Regulation of mammary morphogenesis: evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor betal. Devel Biol 152:354–362, 1992.Google Scholar
  30. 30.
    Spicer DV, Pike MC: Epidemiology of breast cancer.In: Lobo RA (ed) Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Raven Press, New York, 1994, pp 315–324.Google Scholar
  31. 31.
    Peto R: Epidemiology, multistage models, and shortterm mutagenicity tests.In: Hiatt HH, Watson JD, Winsten JE (eds) Origins of Human Cancer: Book C, Human Risk Assessment. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1977, pp 1403–1428.Google Scholar
  32. 32.
    Trichopoulos DB, MacMahon B, Cole P: Menopause and breast cancer risk. J Natl Cancer Inst 48:605–613, 1972.Google Scholar
  33. 33.
    Feinleib M: Breast cancer and artificial menopause: a cohort study. J Natl Cancer Inst 41:315–329, 1968.Google Scholar
  34. 34.
    Hirayama T, Wynder EL: A study of the epidemiology of cancer of the breast. II. The influence of hysterectomy. Cancer 15:28–38, 1962.Google Scholar
  35. 35.
    Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC: Do regular ovulatory cycles increase breast cancer risk? Cancer 56:1206–1208, 1985.Google Scholar
  36. 36.
    Mishell Jr DR, Kharma KM, Thorneycroft IH, Nakamura RM: Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynecol 113:372–376, 1972.Google Scholar
  37. 37.
    Jeppsson S, Johansson EDB, Ljungberg O, Sjoberg N-O: Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA). Estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea. Acta Obstet Gynecol Scand 56:43–48, 1977.Google Scholar
  38. 38.
    Lee NC, Rosero-Bixby L, Oberle MW, Grimaldo C, Whately AS, Rovira EZ: A case-control study of breast cancer and hormonal contraception in Costa Rica. J Natl Cancer Inst 79:1247–1254, 1987.Google Scholar
  39. 39.
    Paul C, Skegg DCG, Spears GFS: Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. Br Med J 299:759–762, 1989.Google Scholar
  40. 40.
    Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C: The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321:293–297, 1989.Google Scholar
  41. 41.
    Persson I, Yuen J, Bergkvist L, Adami H-O, Hoover R, Schairer C: Combined oestrogen-progestogen replacement and breast cancer risk. Lancet 340:1044, 1992.Google Scholar
  42. 42.
    Zumoff B: Relationship of obesity to blood estrogens. Cancer Res 42:3289s-3294s, 1982.Google Scholar
  43. 43.
    Shoupe D. Effect of body weight on reproductive function.In: Mishell DR Jr, Davajan V, Lobo RA (eds) Infertility, Contraception and Reproductive Endocrinology, third ed. Blackwell Scientific Publications, Boston, 1991, pp 288–316.Google Scholar
  44. 44.
    Pike M, Krailo M, Henderson B, Casagrande J, Hoel D: ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer. Nature 303:767–770, 1983.Google Scholar
  45. 45.
    MacMahon B, Cole P, Brown JB, Aoki K, Lin TM, Morgan RW, Woo N-C: Urine estrogen profiles of Asian and North American Women. Int J Cancer 14:161–167, 1974.Google Scholar
  46. 46.
    Goldin BR, Adlercreutz H, Gorbach SL, Woods MN, Dwyer JT, Conlon T, Bohn E, Gershoff SN: The relationship between estrogen levels and diets of Caucasian American and Oriental immigrant women. Am J Clin Nutr 44:945–953, 1986.Google Scholar
  47. 47.
    Bernstein L, Yuan J-M, Ross RK, Pike MC, Lobo RA, Stanczyk F, Gao Y-T, Henderson BE: Serum hormone levels in premenopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies. Cancer Causes Control 1:51–58, 1990.Google Scholar
  48. 48.
    Key TJA, Chen J, Wang DY, Pike MC, Boreham J: Sex hormones in women in rural China and in Britain. Br J Cancer 62:631–636, 1990.Google Scholar
  49. 49.
    Tolis G, Comaru-Schally A, Mehta A, Schally A: Failure to interrupt established pregnancy in humans by d-tryptophan-6-luteinizing hormone-releasing hormone. Fertil Steril 36:241–242, 1981.Google Scholar
  50. 50.
    Casper R, Yen S: Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor. Science 205:408–410, 1979.Google Scholar
  51. 51.
    Sheehan K, Casper R, Yen S: Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: a model for fertility control. Science 215:170–172, 1982.Google Scholar
  52. 52.
    Nillius S, Bergquist C, Wide L: Inhibition of ovulation in women by chronic treatment with a stimulatory LHRH analogue — a new approach to birth control. Contraception 17:537–545, 1978.Google Scholar
  53. 53.
    Bergquist C, Nillius S, Wide L: Peptide contraception in women. Upsala J Med Sci 89:99–106, 1984.Google Scholar
  54. 54.
    Hardt W, Schmidt-Gollwitzer M: Sustained gonadal suppression in fertile women with the LHRH agonist buserelin. Clin Endocrinol 19:613–617, 1983.Google Scholar
  55. 55.
    Schmidt-Gollwitzer M, Hardt W, Schmidt-Gollwitzer K, von der Ohe M, Nevinny-Stickel J: Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control? Contraception 23:187–195, 1981.Google Scholar
  56. 56.
    Brenner P, Shoupe D, Mishell D: Ovulation inhibition with nafarelin acetate nasal administration for six months. Contraception 32:531–551, 1985.Google Scholar
  57. 57.
    LeMay A, Faure N, Labrie F, Fazekas A: Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonists dosing in combination with gestagen-induced bleeding. Fertil Steril 43:868–877, 1985.Google Scholar
  58. 58.
    Kuhl H, Jung C, Taubert H: Contraception with an LHRH agonist: effect on gonadotrophin and steriod secretion patterns. Clin Endocrinol 21:179–188, 1984.Google Scholar
  59. 59.
    Spicer DV, Pike MC, Pike A, Rude R, Shoupe D, Richardson J: Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception 47:427–444, 1993.Google Scholar
  60. 60.
    Brenner PF: The menopausal syndrome. Obstet Gynecol 72:6S-11S, 1988.Google Scholar
  61. 61.
    Lemay A, Maheux R, Faure N, Jean C, Fazekas ATA: Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 41:863–871, 1984.Google Scholar
  62. 62.
    Steingold K, Cedars M, Lu J, Randle D, Judd H, Meldrum D: Treatment of endometriosis with a longacting gonadotropin-releasing hormone agonist. Obstet Gynecol 69:403–411, 1987.Google Scholar
  63. 63.
    George M, Lhomme C, Lefort J, Gras C, Comoru-Schally A, Schally A: Long-term use of an LHRH agonist in the management of uterine leiomyomas: a study of 17 cases. Int J Fertil 34:19–24, 1989.Google Scholar
  64. 64.
    Ronnberg L, Koskimies A, Laatikainen T, Ranta T, Saastamoinen J: Efficacy of gonadotropin-releasing hormone agonist (buserelin) in the treatment of endometriosis. Acta Obstet Gynecol Scand 68:49–53, 1989.Google Scholar
  65. 65.
    Dennerstein L: Psychologic changes.In: Mishell D Jr (ed) Menopause, Physiology and Pharmacology. Yearbook Medical Publishers, Chicago, 1987, pp 115–126.Google Scholar
  66. 66.
    Meldrum D: Treatment of hot flushes.In: Mishell D Jr (ed) Menopause, Physiology and Pharmacology. Yearbook Medical Publishers, Chicago, 1987, pp 141–150.Google Scholar
  67. 67.
    Selby PL, Peacock M: Dose dependent response of symptoms, pituitary, and bone to transdermal estrogen in postmenopausal women. Br Med J 293:1337–1339, 1986.Google Scholar
  68. 68.
    Lobo RA, McCormick W, Singer F, Roy S: Depomedroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 63:1–5, 1984.Google Scholar
  69. 69.
    Hammarback S, Backstrom T, Holst J, von Schoultz B, Lyrenas S: Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestogen postmenopausal replacement therapy. Acta Obstet Gynecol Scand 64:393–397, 1985.Google Scholar
  70. 70.
    Magos AL, Brewster E, Singh R, O'Dowd T, Brincat M, Studd JW: The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 93:1290–1296, 1986.Google Scholar
  71. 71.
    Holst J, Backstrom T, Hammarback S, Schoultz BV: Progestogen addition during estrogen replacement therapy — effects on vasomotor symptoms and mood. Maturitas 11:13–20, 1989.Google Scholar
  72. 72.
    Mezrow G, Shoupe D, Spicer D, Pike M: Depot leuprolide acetate (GnRH) with estrogen and progestin addback for longterm treatment of premenstrual syndrome. Society for Gynecologic Investigation, 1992.Google Scholar
  73. 73.
    Mishell DR Jr: Oral steroid contraceptives.In: Mishell D Jr, Davajan V, Lobo RA (eds) Infertility, Contraception and Reproductive Endocrinology (3d ed). Blackwell Scientific Publications, Boston, 1991, pp 839–871.Google Scholar
  74. 74.
    Henderson B, Ross R, Lobo R, Pike M, Mack T: Reevaluating the role of progestogen therapy after the menopause. Fertil Steril 49 (Suppl):9–15, 1988.Google Scholar
  75. 75.
    Bush T, Miller V: Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins.In: Mishell D Jr (ed) Menopause, Physiology and Pharmacology. Yearbook Medical Publishers, Chicago, 1987, pp 187–208.Google Scholar
  76. 76.
    Kannel W, Gordon T: Cardiovascular effects of the menopause.In: Mishell D Jr (ed) Menopause, Physiology and Pharmacology. Yearbook Medical Publishers, Chicago, 1987, pp 91–102.Google Scholar
  77. 77.
    Mann J, Lewis B, Shepherd J, Winder A, Fenster S, Rose L, Morgan B: Blood lipid concentrations and other cardiovascular risk factors: distribution, prevalence, and detection in Britain. Br Med J 296:1702–1706, 1988.Google Scholar
  78. 78.
    Liskin L, Blackburn R: Hormonal contraception: new long-acting methods. Popul Rep Series K(3), 1987.Google Scholar
  79. 79.
    Ruegsegger P, Dambacher MA, Ruegsegger E, Fischer JA, Anliker M: Bone loss in premenopausal and postmenopausal women. J Bone and Joint Surg 66:1015–1023, 1984.Google Scholar
  80. 80.
    Nilas L, Christiansen C: Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause. Eur J Clin Invest 18:529–534, 1988.Google Scholar
  81. 81.
    Riggs B, Wahner H, Seeman E, Offord K, Dunn W, Mazess R, Johnson K, Melton L: Changes in bone mineral density of the proximal femur and spine with aging. J Clin Invest 70:716–723, 1982.Google Scholar
  82. 82.
    Drinkwater BL, Chesnut CH III: Bone density changes during pregnancy and lactation in active women: a longitudinal study. Bone Miner 14:153–160, 1991.Google Scholar
  83. 83.
    Hayslip CC, Klein TA, Wray HL, Duncan WE: The effects of lactation on bone mineral content in healthy postpartum women. Obstet Gynecol 73:588–592, 1989.Google Scholar
  84. 84.
    Sowers M, Corton G, Shapiro B, Jannausch ML, Crutchfield M, Smith ML, Randolph JF, Hollis B: Changes in bone density with lactation. JAMA 269:3130–3135, 1993.Google Scholar
  85. 85.
    Koetting CA, Wardlaw GM: Wrist, spine, and hip bone density in women with variable histories of lactation. Am J Clin Nutr 48:1479–1481, 1988.Google Scholar
  86. 86.
    Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid I: Bone density in women receiving depot medroxyprogesterone acetate for contraception. Br Med J 303:13–16, 1991.Google Scholar
  87. 87.
    Matta WH, Shaw RW, Hesp R, Evans R: Reversible trabecular bone density loss following induced hypooestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrin 29:45–51, 1988.Google Scholar
  88. 88.
    Lobo RA: Prevention of postmenopausal osteoporosis.In: Mishell D Jr (ed) Menopause, Physiology and Pharmacology. Yearbook Medical Publishers, Chicago, 1987, pp 165–186.Google Scholar
  89. 89.
    Ettinger B, Genant H, Cann C: Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Int Med 106:40–45, 1987.Google Scholar
  90. 90.
    Genant H, Cann C, Ettinger B, Gordan G: Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 97:699–705, 1982.Google Scholar
  91. 91.
    Watts N, Notelovits M, Timmons C, Addison W, Wiita B, Downey L: Effects of oral esterified estrogens and esterified estrogens + androgen on bone mineral denisty in postmenopausal women. The North American Menopause Society, 2nd Annual Meeting. Montreal, Canada, 1991, 82.Google Scholar
  92. 92.
    Steingold K, De Ziegler D, Cedars M, Meldrum DR, Lu JKH, Judd HL, Chang RJ: Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J Clin Endorinol Metab 65:773–778, 1987.Google Scholar
  93. 93.
    Studd JWW, Chakravarti S, Collins WP: Plasma hormone profiles after the menopause and bilateral oophorectomy. Postgrad Med J 54:25–30, 1978.Google Scholar
  94. 94.
    Longcope, Hui, Johnston: Free estradiol, free testosterone, and sex hormone-binding globulin in perimenopausal women. J Clin Endocrinol Metab 64:513–518, 1987.Google Scholar
  95. 95.
    Steinberg K, Freni-Titulaer LW, DePuey E, Miller D, Sgoutas D, Coralli C, Phillips D, Rogers T, Clark R: Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab 69:533–39, 1989.Google Scholar
  96. 96.
    Studd J, Thom M, Paterson M: The prevention and treatment of endometrial pathology in postmenopausal women receiving exogenous oestrogens.In: Pasetto W, Pavletti R, Lambrus J (eds) The Menopause and Postmenopause. MTP Press, Lancaster UK, 1980, pp 127–138.Google Scholar
  97. 97.
    Whitehead M, Lane G, Siddle N, Townsend P, King R: Avoidance of endometrial hyperstimulation in estrogen-treated postmenopausal women. Semin Reprod Endocrinol 1:41–54, 1983.Google Scholar
  98. 98.
    Schiff I, Sela H, Cramer D, Tulchinsky D, Ryan K: Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 37:79–82, 1982.Google Scholar
  99. 99.
    Matta W, Shaw R, Burford G: Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women. Fertil Steril 49:163–165, 1988.Google Scholar
  100. 100.
    Friedman A, Rein M, Harrison-Atlas D, Garfield J, Doubilet P: A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil Steril 52:728–733, 1989.Google Scholar
  101. 101.
    Schlaff W, Zerhouni E, Huth J, Chen J, Damewood M, Rock J: A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obstet Gynecol 74:856–862, 1989.Google Scholar
  102. 102.
    Zorn J-R, Mathieson J, Risquez F, Comaru-Schally A, Schally A: Treatment of endometriosis with a delayed release preparation of the agonist D-Trp-luteinizing hormone-releasing hormone: long-term follow-up in a series of 50 patients. Fertil Steril 53:401–406, 1990.Google Scholar
  103. 103.
    Stanford JL, Thomas DB: Depot-medroxyprogester-one acetate (DMPA) and risk of epithelial ovarian cancer. Int J Cancer 49:191–195, 1991.Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Darcy V. Spicer
    • 1
  • Malcolm C. Pike
    • 1
  1. 1.Departments of Medicine and Preventive MedicineUniversity of Southern California School of Medicine, and the Kenneth Norris Jr. Cancer Hospital and Research InstituteLos AngelesUSA

Personalised recommendations